SEC Info - Sanofi - ‘6-K’ for 5/26/16

SEC Info℠

Home

Help

Please Sign In

Sanofi – ‘6-K’ for 5/26/16

On: Thursday, 5/26/16, at 3:02pm ET · For: 5/26/16 · Accession #: 1193125-16-603989 · File #: 1-31368

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 5/26/16  Sanofi                            6-K         5/26/16    3:297K                                   RR Donnelley/FA

Report by a Foreign Private Issuer — Form 6-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 6-K         Report by a Foreign Private Issuer                  HTML     11K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     40K 
 3: EX-99.2     Miscellaneous Exhibit                               HTML     14K

6-K — Report by a Foreign Private Issuer

This is an HTML Document rendered as filed. [ Alternative Formats ]

6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE

ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2016

Commission File Number: 001-31368

SANOFI

(Translation of registrant’s name into English)

54, rue La Boétie, 75008 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ¨ No x

If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

In May 2016, Sanofi issued the statements attached hereto as Exhibit 99.1 to 99.3 which are incorporated herein by reference.

Exhibit List


Exhibit No.		Description

Exhibit 99.1		Press release dated May 23, 2016: Sanofi Announces Changes to Executive Committee Aligned to its Strategic Roadmap 2020

Exhibit 99.2		Press release dated May 25, 2016: FDA Advisory Committee Recommends Approval of Sanofi Treatment for Adults with Type 2 Diabetes

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Dated: May 26, 2016		SANOFI

	By	/S/ Alexandra Roger
		Name:	Alexandra Roger
		Title:	Head of Securities Law and Capital Markets

Exhibit Index


Exhibit No.		Description

Exhibit 99.1		Press release dated May 23, 2016: Sanofi Announces Changes to Executive Committee Aligned to its Strategic Roadmap 2020

Exhibit 99.2		Press release dated May 25, 2016: FDA Advisory Committee Recommends Approval of Sanofi Treatment for Adults with Type 2 Diabetes

Dates Referenced Herein and Documents Incorporated by Reference

This ‘6-K’ Filing	Date	Other Filings

Filed on / For Period End:	5/26/16
	5/25/16	6-K, DFAN14A, PREC14A
	5/23/16
		List all Filings

↑Top

Filing Submission 0001193125-16-603989 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)